Jim Connelly, MD
Washington University School of Medicine, St. Louis, MO, 2003
Pediatric Residency-University of Michigan Medical School, Ann Arbor, MI
Pediatric Hematology/Oncology Fellowship-University of Michigan Medical School, Ann Arbor, MI
Pathology Research Fellowship-University of Michigan Medical School, Ann Arbor, MI
Primary Immune Deficiency, Bone Marrow Failure, Neutropenia, Sickle Cell Disease
Dr. Connelly joined the Vanderbilt Pediatric Hematology/Oncology program in January 2016 as a member of the Pediatric Stem Cell Transplant team. Dr. Connelly received his medical degree from Washington University Medical School and performed his pediatric residency and fellowship training at the University of Michigan. He spent his early faculty years at the University of Michigan where he helped develop and direct the Comprehensive Immuno-Hematology Program. Dr. Connelly has extensive expertise in non-malignant transplant and his primary clinical and research interests are in patients with immunologic and bone marrow failure disorders. On a national level, he serves as the research chair for the National Immuno-hematology Clinical Education and Research (NICER) consortium, is a member of the Severe Chronic Neutropenia International Registry (SCNIR) Board where he serves as the primary transplant physician, and is involved with leading research consortia for the development and implementation of safer, more effective transplant strategies for non-malignant disorders. At Vanderbilt, Dr. Connelly manages all non-malignant bone marrow transplants and is the director of the Comprehensive Hematology, Immunology, and Infectious Disease Program (CHIIP). The CHIIP clinic offers care for complex immune disorders and allows patients to receive expertise from multiple sub-specialists including immunology, hematology, infectious disease, and bone marrow transplant during one clinic visit. Through the CHIIP clinic, Dr. Connelly collaborates with clinical and basic science colleagues at Vanderbilt to study pediatric and adult patients with rare conditions of the immune system through the Human Immunology Discovery Initiative (HIDI). This research platform allows Vanderbilt scientists to study how immune cells are impaired in disease and perform extensive genetic analysis to diagnose patients with unknown disorders of the immune system. His additional area of scientific interest is in the development of malignancy in neutropenic disorders and provision of safer transplant strategies for chronic neutropenia and has international collaborations to study these topics. Through these efforts, patients at Vanderbilt have access to science discovery to understand and diagnose their immune system defects and receive state-of-the art treatments including bone marrow transplant for blood and immune disorders.